These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
232 related articles for article (PubMed ID: 22125021)
1. [Denosumab - a new option in the treatment of osteoporosis]. Franek E Endokrynol Pol; 2011; 62 Suppl 2():37-41. PubMed ID: 22125021 [TBL] [Abstract][Full Text] [Related]
2. Denosumab--a new option in the treatment of osteoporosis. Franek E Endokrynol Pol; 2011; 62(1):79-83. PubMed ID: 21365584 [TBL] [Abstract][Full Text] [Related]
3. Treatment of osteoporosis with denosumab. Lewiecki EM Maturitas; 2010 Jun; 66(2):182-6. PubMed ID: 20236778 [TBL] [Abstract][Full Text] [Related]
4. [The role of rank-ligand inhibition in the treatment of postmenopausal osteoporosis]. Varenna M; Gatti D Reumatismo; 2010; 62(3):163-71. PubMed ID: 21052563 [TBL] [Abstract][Full Text] [Related]
5. Role of RANK ligand and denosumab, a targeted RANK ligand inhibitor, in bone health and osteoporosis: a review of preclinical and clinical data. Dempster DW; Lambing CL; Kostenuik PJ; Grauer A Clin Ther; 2012 Mar; 34(3):521-36. PubMed ID: 22440513 [TBL] [Abstract][Full Text] [Related]
6. Denosumab for prevention of fractures in postmenopausal women with osteoporosis. Cummings SR; San Martin J; McClung MR; Siris ES; Eastell R; Reid IR; Delmas P; Zoog HB; Austin M; Wang A; Kutilek S; Adami S; Zanchetta J; Libanati C; Siddhanti S; Christiansen C; N Engl J Med; 2009 Aug; 361(8):756-65. PubMed ID: 19671655 [TBL] [Abstract][Full Text] [Related]
7. [Denosumab for treatment of postmenopausal osteoporosis]. Syversen U; Halse JI; Geisler J; Eriksen EF Tidsskr Nor Laegeforen; 2011 Oct; 131(19):1893-6. PubMed ID: 21984295 [TBL] [Abstract][Full Text] [Related]
8. Denosumab for the treatment of osteoporosis. Iqbal J; Sun L; Zaidi M Curr Osteoporos Rep; 2010 Dec; 8(4):163-7. PubMed ID: 20857349 [TBL] [Abstract][Full Text] [Related]
9. Clinical use of denosumab for the treatment for postmenopausal osteoporosis. Lewiecki EM Curr Med Res Opin; 2010 Dec; 26(12):2807-12. PubMed ID: 21050058 [TBL] [Abstract][Full Text] [Related]
10. Effects of denosumab on bone mineral density and bone turnover in postmenopausal women. Wensel TM; Iranikhah MM; Wilborn TW Pharmacotherapy; 2011 May; 31(5):510-23. PubMed ID: 21923432 [TBL] [Abstract][Full Text] [Related]
11. Effects of denosumab on cortical and trabecular microarchitecture: evidences from clinical studies. Iolascon G; Resmini G; Tarantino U Aging Clin Exp Res; 2013 Oct; 25 Suppl 1():S19-22. PubMed ID: 24046050 [TBL] [Abstract][Full Text] [Related]
16. Effects of denosumab on bone turnover markers in postmenopausal osteoporosis. Eastell R; Christiansen C; Grauer A; Kutilek S; Libanati C; McClung MR; Reid IR; Resch H; Siris E; Uebelhart D; Wang A; Weryha G; Cummings SR J Bone Miner Res; 2011 Mar; 26(3):530-7. PubMed ID: 20839290 [TBL] [Abstract][Full Text] [Related]
17. A new antiresorptive approach to the treatment of fragility fractures: long-term efficacy and safety of denosumab. Tarantino U; Celi M; Feola M; Liuni FM; Resmini G; Iolascon G Aging Clin Exp Res; 2013 Oct; 25 Suppl 1():S65-9. PubMed ID: 24046047 [TBL] [Abstract][Full Text] [Related]
18. Treatment with denosumab reduces the incidence of new vertebral and hip fractures in postmenopausal women at high risk. Boonen S; Adachi JD; Man Z; Cummings SR; Lippuner K; Törring O; Gallagher JC; Farrerons J; Wang A; Franchimont N; San Martin J; Grauer A; McClung M J Clin Endocrinol Metab; 2011 Jun; 96(6):1727-36. PubMed ID: 21411557 [TBL] [Abstract][Full Text] [Related]